Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?
0
/
RSS Feed
Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.
Share
